Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Artivion stock price target raised on revenue growth

EditorAhmed Abdulazez Abdulkadir
Published 05/07/2024, 07:06 PM
AORT
-

On Tuesday, Artivion Inc. (NYSE: AORT) saw its price target increased to $30.00 from the previous $25.00 by Needham, while the firm maintained a Buy rating on the stock. This adjustment follows Artivion's first-quarter financial results for 2024, which surpassed consensus estimates in terms of revenue and EBITDA. Artivion's management has also updated its revenue outlook for the year, raising the lower end of its 2024 guidance while keeping its adjusted EBITDA forecast steady.

The company reported a year-over-year constant currency revenue growth, accelerating to 16% in the first quarter of 2024, up from 15% in the last quarter of 2023. Additionally, Artivion's gross margin remained consistent year-over-year, and its operating margin increased significantly by 530 basis points. These financial improvements have been attributed to strong performances across Artivion's key product segments.

Specifically, tissue products experienced a 26% rise, stent grafts increased by 19%, the On-X product line grew by 11%, and BioGlue sales were up by 1%, all measured in constant currency terms. Geographically, Artivion's sales in Latin America saw a robust increase of 22% in constant currency. However, the Asia Pacific region faced a 3% decline due to the timing of distributor orders.

Needham's outlook on Artivion is optimistic, with projections of sustained double-digit revenue growth and even faster EBITDA growth for the company. The firm's confidence in Artivion's financial trajectory and market performance is reflected in the raised price target and reiterated Buy rating.

InvestingPro Insights

As Artivion Inc. (NYSE: AORT) navigates a period of financial growth and market optimism, real-time data from InvestingPro offers a deeper dive into the company's performance and valuation. Artivion's market capitalization stands at $878.83 million, with a notable revenue growth of 12.82% over the last twelve months as of Q4 2023. This aligns with the company's reported acceleration in revenue, further substantiated by a gross profit margin of 64.74%, indicating strong profitability on its sales.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro Tips highlight that Artivion has experienced a strong return over the last three months, with a 26.17% price total return, and an even more impressive six-month price uptick of 52.79%. This suggests a positive market sentiment, which is reinforced by the company's stock trading near its 52-week high at 96.35% of the peak value. Additionally, analysts have a favorable outlook, predicting that Artivion will be profitable this year, a projection that aligns with Needham's optimistic assessment.

For investors seeking to leverage these insights, InvestingPro provides a comprehensive suite of additional tips, currently listing 12 more for Artivion. To access these valuable resources and enhance your investment strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/AORT.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.